DE10134721A1 - Tetrahydrochinoxaline - Google Patents

Tetrahydrochinoxaline

Info

Publication number
DE10134721A1
DE10134721A1 DE10134721A DE10134721A DE10134721A1 DE 10134721 A1 DE10134721 A1 DE 10134721A1 DE 10134721 A DE10134721 A DE 10134721A DE 10134721 A DE10134721 A DE 10134721A DE 10134721 A1 DE10134721 A1 DE 10134721A1
Authority
DE
Germany
Prior art keywords
compounds
halogen
alkyl
phenyl
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10134721A
Other languages
German (de)
English (en)
Inventor
Bettina Beyreuther
Michael Hahn
Christopher Kallus
Joachim Krueger
Heinrich Meier
Elke Reismueller
Leila Telan
Reilinde Wittka-Nopper
Mathias Kroll
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Priority to DE10134721A priority Critical patent/DE10134721A1/de
Priority to CA002454007A priority patent/CA2454007A1/en
Priority to EP02762319A priority patent/EP1411948A1/de
Priority to JP2003513565A priority patent/JP2004536858A/ja
Priority to US10/483,464 priority patent/US20040235849A1/en
Priority to PCT/EP2002/007416 priority patent/WO2003007958A1/de
Publication of DE10134721A1 publication Critical patent/DE10134721A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE10134721A 2001-07-17 2001-07-17 Tetrahydrochinoxaline Withdrawn DE10134721A1 (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DE10134721A DE10134721A1 (de) 2001-07-17 2001-07-17 Tetrahydrochinoxaline
CA002454007A CA2454007A1 (en) 2001-07-17 2002-07-04 Tetrahydroquinoxalines acting as bradykinin antagonists
EP02762319A EP1411948A1 (de) 2001-07-17 2002-07-04 Tetrahydrochinoxaline als bradykininantagonisten
JP2003513565A JP2004536858A (ja) 2001-07-17 2002-07-04 テトラヒドロキノキサリン類
US10/483,464 US20040235849A1 (en) 2001-07-17 2002-07-04 Tetrahydroquinoxalines acting as bradykinin antagonists
PCT/EP2002/007416 WO2003007958A1 (de) 2001-07-17 2002-07-04 Tetrahydrochinoxaline als bradykininantagonisten

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10134721A DE10134721A1 (de) 2001-07-17 2001-07-17 Tetrahydrochinoxaline

Publications (1)

Publication Number Publication Date
DE10134721A1 true DE10134721A1 (de) 2003-02-06

Family

ID=7692082

Family Applications (1)

Application Number Title Priority Date Filing Date
DE10134721A Withdrawn DE10134721A1 (de) 2001-07-17 2001-07-17 Tetrahydrochinoxaline

Country Status (6)

Country Link
US (1) US20040235849A1 (enExample)
EP (1) EP1411948A1 (enExample)
JP (1) JP2004536858A (enExample)
CA (1) CA2454007A1 (enExample)
DE (1) DE10134721A1 (enExample)
WO (1) WO2003007958A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003228825A1 (en) * 2002-05-03 2003-11-17 Elan Pharmaceuticals, Inc. Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists
EP1549622A1 (en) * 2002-10-10 2005-07-06 Elian Pharmaceuticals Inc. Sulfonylbenzodiazepinone acetamides as bradykinin antagonists
US6908921B2 (en) 2002-12-13 2005-06-21 Merck & Co., Inc. Quinoxalinone derivatives as bradykinin B1 antagonists
CA2522084A1 (en) 2003-04-10 2004-10-28 Amgen Inc. Cyclic amine derivatives and their use in the treatment of inflammation-related disorders mediated by bradykinin
DE602004016992D1 (de) 2003-05-02 2008-11-20 Elan Pharm Inc 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3-carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen
WO2005061467A2 (en) 2003-06-20 2005-07-07 Amgen Inc. Piperazine derivatives as bradykinin antagonists
EP1878728A3 (en) * 2003-06-20 2008-01-30 Amgen Inc. Derivatives of piperazine and higher homologues thereof for the treatment of inflammation-related disorders
US20070179155A1 (en) * 2003-06-20 2007-08-02 Brian Smith N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
CA2534887A1 (en) * 2003-08-08 2005-02-24 Janssen Pharmaceutica, N.V. Process for the preparation of 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds
US7662811B2 (en) 2004-07-15 2010-02-16 Amgen Inc. 1,2,3,4-tetrahydropyrazin-2-yl acetamides and methods of use
JPWO2006064780A1 (ja) * 2004-12-14 2008-06-12 塩野義製薬株式会社 便秘治療剤
AU2006321919A1 (en) * 2005-12-07 2007-06-14 Amgen Inc. Bradykinin 1 receptor antagonists
MX358640B (es) 2008-01-04 2018-08-29 Intellikine Llc Isoquinolin-1 (2h) -onas y tieno [2,3-d]pirimidin-4(3h) -onas substituidas, y metodos de uso de las mismas.
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP2316820A1 (en) 2009-10-28 2011-05-04 Dompe S.p.A. 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them
TWI546305B (zh) 2011-01-10 2016-08-21 英菲尼提製藥股份有限公司 製備異喹啉酮之方法及異喹啉酮之固體形式
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
EP2895204B1 (en) * 2012-09-13 2020-10-21 Provincial Health Services Authority Compositions targeting bradykinin receptor b1 for medical imaging of cancer and other disorders
CN105102000B (zh) 2012-11-01 2021-10-22 无限药品公司 使用pi3激酶亚型调节剂的癌症疗法
EP2813502B1 (en) 2013-06-14 2017-01-04 Dompé farmaceutici s.p.a. Bradykinin receptor antagonists and pharmaceutical compositions containing them
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
EP4294808A1 (en) 2021-02-19 2023-12-27 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
JP2024508794A (ja) 2021-02-19 2024-02-28 スドー バイオサイエンシーズ リミテッド Ｔｙｋ２阻害剤およびその使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3247196A (en) * 1962-06-21 1966-04-19 Ciba Geigy Corp Nuomega-derivatives of 7-(nu-amino-adipoylamino)-cephalosporanic acid
US3635971A (en) * 1970-06-18 1972-01-18 Abbott Lab 3 (3 4-dihydro-3-oxo-2-quinoxalinyl) propionamides
DK0509398T3 (da) * 1991-04-15 2002-01-14 Aventis Pharma Gmbh Quinoxaliner, fremgangsmåder til deres fremstilling samt deres anvendelse
DE19712960A1 (de) * 1997-03-27 1998-10-01 Hoechst Ag Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten
AU2003228825A1 (en) * 2002-05-03 2003-11-17 Elan Pharmaceuticals, Inc. Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists

Also Published As

Publication number Publication date
JP2004536858A (ja) 2004-12-09
CA2454007A1 (en) 2003-01-30
US20040235849A1 (en) 2004-11-25
WO2003007958A1 (de) 2003-01-30
EP1411948A1 (de) 2004-04-28

Similar Documents

Publication Publication Date Title
DE10134721A1 (de) Tetrahydrochinoxaline
DE69617665T2 (de) Benzmidazolverbindungen und ihre verwendung als modulatoren des gabaa-rezeptor-komplexes
DE69528257T2 (de) KONDENSIERTE HETEROCYCLISCHE VERBINDUNG, DEREN HERSTELLUNG UND VERWENDUNG ALS GnRH ANTAGONISTEN
DE60021282T2 (de) Carbamat-derivate als muscarin-rezeptor antonisten
DE60005560T2 (de) Neuartiger p2x 7 rezeptor-antagonisten zur verwendung in der behandlung von entzündlichen, immuninduzierten erkrankungen oder erkrankungen des herz-kreislauf-systems
AU722883B2 (en) Cyclopentyl tachykinin receptor antagonists
DE68919148T2 (de) Pyrrolo[1,4]benzodiazepinderivate.
DE60012223T2 (de) Harnstoffderivate wirksam als muscarinrezeptor-antagonisten
DE69430988T2 (de) Pyrazolotriazine mit interleukin-1 und tumor necrosis faktor inhibitor wirkung
DE69422303T2 (de) Neue 4-piperidinyl substituierte lactame als neukokinin 2 rezeptor antagonisten zur behandlung von asthma
DE69212346T2 (de) Diazotierte heterocyclische Derivate aus Stickstoff, substituiert durch eine Biphenylgruppe, ihre Herstellung, und diese enthaltende pharmazeutische Zubereitungen
DE69524598T2 (de) Kondensierte imidazolderivate, ihre herstellung und verwendung
EP0531883A1 (de) Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE10230605A1 (de) Substituierte Imidazotriazine
DE3883033T2 (de) Heterocyclische Verbindungen und ihre Herstellung und Anwendung.
DE69704060T2 (de) Tetrahydroisochinolinderivate und ihre pharmazeutische anwendung
EP1521756A1 (de) Heterocyclisch substituierte imidazotriazine
DE69722281T2 (de) 3-Aza-piperidon- (Tetrahydropyrimidin-2-on) und 3-Oxa-piperidon (1,3-Oxazin-2-on) Derivate, deren Herstellung und deren Verwendung als Tachykinin/Neurokinin Antagonisten
WO2005028451A1 (de) Tetrahydrochinoxaline und ihre verwendung als m2 acetylcholinrezeptor agonisten
DE60017446T2 (de) Isochinolin- und Chinazolinderivate mit kombinierter 5-HT1A-, 5-HT1B- und 5-HT1D- Rezeptoraffinität
DE19816983A1 (de) Bicyclen, deren Herstellung und deren Verwendung als Arzneimittel
DE69110135T2 (de) Neuroleptische perhydro-1h-pyrido(1,2-alpha)pyrazine.
DE10147672A1 (de) Substituierte 2,5-Diamidoindole und ihre Verwendung
DE69903319T2 (de) Fkbp inhibitoren
DE69311123T2 (de) Cyclische benzylamino-, benzylamido- und benzylimido derivate als antipsychotische wirkstoffe

Legal Events

Date Code Title Description
8127 New person/name/address of the applicant

Owner name: BAYER HEALTHCARE AG, 51373 LEVERKUSEN, DE

8139 Disposal/non-payment of the annual fee